KR20030022850A - 인간 골수종 세포주 - Google Patents

인간 골수종 세포주 Download PDF

Info

Publication number
KR20030022850A
KR20030022850A KR10-2003-7000213A KR20037000213A KR20030022850A KR 20030022850 A KR20030022850 A KR 20030022850A KR 20037000213 A KR20037000213 A KR 20037000213A KR 20030022850 A KR20030022850 A KR 20030022850A
Authority
KR
South Korea
Prior art keywords
cells
human
cell line
antibody
myeloma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2003-7000213A
Other languages
English (en)
Korean (ko)
Inventor
칼파스아브라함
Original Assignee
캠브리지 유니버시티 테크니칼 서비스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0016824A external-priority patent/GB0016824D0/en
Priority claimed from GB0017139A external-priority patent/GB0017139D0/en
Application filed by 캠브리지 유니버시티 테크니칼 서비스 리미티드 filed Critical 캠브리지 유니버시티 테크니칼 서비스 리미티드
Publication of KR20030022850A publication Critical patent/KR20030022850A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR10-2003-7000213A 2000-07-07 2001-07-09 인간 골수종 세포주 Ceased KR20030022850A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0016824.5 2000-07-07
GB0016824A GB0016824D0 (en) 2000-07-07 2000-07-07 Human monoclonal antibodies
GB0017139.7 2000-07-12
GB0017139A GB0017139D0 (en) 2000-07-12 2000-07-12 Human monoclonal antibodies
US27058801P 2001-02-23 2001-02-23
US60/270,588 2001-02-23
PCT/GB2001/003059 WO2002004607A1 (en) 2000-07-07 2001-07-09 Human myeloma cell line

Publications (1)

Publication Number Publication Date
KR20030022850A true KR20030022850A (ko) 2003-03-17

Family

ID=27255800

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7000213A Ceased KR20030022850A (ko) 2000-07-07 2001-07-09 인간 골수종 세포주

Country Status (12)

Country Link
US (1) US7387873B2 (enExample)
EP (1) EP1299524B1 (enExample)
JP (1) JP2004502454A (enExample)
KR (1) KR20030022850A (enExample)
CN (1) CN100497601C (enExample)
AT (1) ATE440945T1 (enExample)
AU (2) AU2001269300B2 (enExample)
CA (1) CA2415484A1 (enExample)
DE (1) DE60139694D1 (enExample)
IL (1) IL153641A0 (enExample)
NO (1) NO20030019L (enExample)
WO (1) WO2002004607A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE440945T1 (de) 2000-07-07 2009-09-15 Cambridge Entpr Ltd Menschliche myelom zelllinie
WO2003052082A2 (en) 2001-12-18 2003-06-26 Whitehead Institute For Biomedical Research Fusion partner cells and uses thereof
US8460745B2 (en) * 2009-09-20 2013-06-11 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
US8678046B2 (en) 2009-09-20 2014-03-25 Medtronic Vascular, Inc. Apparatus and methods for loading a drug eluting medical device
US20110070358A1 (en) 2009-09-20 2011-03-24 Medtronic Vascular, Inc. Method of forming hollow tubular drug eluting medical devices
US8333801B2 (en) 2010-09-17 2012-12-18 Medtronic Vascular, Inc. Method of Forming a Drug-Eluting Medical Device
US8616040B2 (en) 2010-09-17 2013-12-31 Medtronic Vascular, Inc. Method of forming a drug-eluting medical device
CN105601734A (zh) * 2016-03-01 2016-05-25 广东医学院附属医院 一种从人外周血记忆性b淋巴细胞制备抗体的方法
CN115161311B (zh) * 2022-08-22 2025-05-06 广东忠信生物科技有限公司 高效筛选分泌单克隆抗体的杂交瘤细胞的方法及其应用
CN115463146B (zh) * 2022-10-14 2024-01-23 浙大城市学院 哇巴因化合物作为在制备抗病毒药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0096839B1 (en) * 1982-06-09 1989-01-25 Asahi Kasei Kogyo Kabushiki Kaisha Method for producing human antibody
US4720459A (en) * 1985-02-14 1988-01-19 Medical College Of Wisconsin Research Foundation, Inc. Myelomas for producing human/human hybridomas
ATE440945T1 (de) 2000-07-07 2009-09-15 Cambridge Entpr Ltd Menschliche myelom zelllinie

Also Published As

Publication number Publication date
DE60139694D1 (de) 2009-10-08
IL153641A0 (en) 2003-07-06
JP2004502454A (ja) 2004-01-29
EP1299524A1 (en) 2003-04-09
ATE440945T1 (de) 2009-09-15
CN100497601C (zh) 2009-06-10
NO20030019L (no) 2003-03-07
WO2002004607A1 (en) 2002-01-17
US20040023339A1 (en) 2004-02-05
AU2001269300B2 (en) 2006-06-22
CN1455813A (zh) 2003-11-12
NO20030019D0 (no) 2003-01-03
CA2415484A1 (en) 2002-01-17
EP1299524B1 (en) 2009-08-26
US7387873B2 (en) 2008-06-17
AU6930001A (en) 2002-01-21

Similar Documents

Publication Publication Date Title
KR100255717B1 (ko) 항체의 생산방법
WO2020228825A1 (en) Engineered immune cells comprsing a recognition molecule
US20070154995A1 (en) Development of human monoclonal antibodies and uses thereof
JPH03236794A (ja) ヒトモノクローン抗体の製造法
KR20120059659A (ko) Ｐａｎ-ｋｉｒ2ｄｌ ｎｋ-수용체 항체 및 진단 및 치료에서의 그 사용 방법
FI85282C (fi) Foerfarande foer framstaellning av permanenta djur- och humancellinjer.
US7387873B2 (en) Human myeloma cell line
AU2001269300A1 (en) Human myeloma cell line
US8859278B2 (en) Fully human hybridoma fusion partner cell lines
JP2004502454A5 (enExample)
US20130196380A1 (en) In vitro process for the preparation of antibodies of the igg type
Lindl Development of human monoclonal antibodies: A review
James Human monoclonal antibody technology
Mozes et al. Nature and function of antigen-specific T-cell lines and their products
JPS6239999B2 (enExample)
WO2022162009A1 (en) Method for rapid identification of cross-reactive and/or rare antibodies
CN120025438A (zh) 一种靶向cd7的人源化抗体、嵌合抗原受体及其应用
Smyrnis The generation of monoclonal antibodies to neural cell type-specific antigenic determinants
MXPA06000841A (es) Metodos y composiciones para aumentar la eficiencia de anticuerpos terapeuticos que utilizan compuestos para potenciar celulas nk

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030107

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20060522

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070426

Patent event code: PE09021S01D

AMND Amendment
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071025

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080425

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20071025

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20070426

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20080523

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20080425

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20090528

Appeal identifier: 2008101004650

Request date: 20080523

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20080523

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20080523

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20071221

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070626

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20060522

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
E801 Decision on dismissal of amendment
PB0601 Maintenance of original decision after re-examination before a trial

Comment text: Report of Result of Re-examination before a Trial

Patent event code: PB06011S01D

Patent event date: 20080723

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20080723

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080523

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20071221

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20070626

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20060522

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20080523

Effective date: 20090528

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20090528

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20080523

Decision date: 20090528

Appeal identifier: 2008101004650